Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia

Roland B. Walter; Laura C. Michaelis; Megan Othus; Geoffrey L. Uy; Jerald P. Radich; Richard F. Little; Sandi Hita; Lalit Saini; James M. Foran; Aaron T. Gerds; Heidi D. Klepin; Annette E. Hay; Sarit Assouline; Jeffrey E. Lancet; Stephen Couban; Mark R. Litzow; Richard M. Stone; Harry P. Erba

doi:10.1002/ajh.24980

Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia

Roland B. Walter, Laura C. Michaelis, Megan Othus, Geoffrey L. Uy, Jerald P. Radich, Richard F. Little, Sandi Hita, Lalit Saini, James M. Foran, Aaron T. Gerds, Heidi D. Klepin, Annette E. Hay, Sarit Assouline, Jeffrey E. Lancet, Stephen Couban, Mark R. Litzow, Richard M. Stone, Harry P. Erba

Medicine

Producción científica: Contribución a una revista › Carta › revisión exhaustiva

13 Citas (Scopus)

Idioma original	English
Páginas (desde-hasta)	E49-E52
Publicación	American Journal of Hematology
Volumen	93
N.º	2
DOI	https://doi.org/10.1002/ajh.24980
Estado	Published - feb. 2018

Nota bibliográfica

Funding Information:
The Older AML Working Group acknowledges Danielle Jenkins (Clinical Information Specialist, the EMMES Corporation) and Dr. Lawrence Baizer (Program Director, Hematologic Malignancies Steering Committees, National Cancer Institute, National Institutes of Health) for their assistance in the organization of our committee. We thank Drs. Wendy Stock, Daniel De Angelo, and Jerry Radich, Co-Chairs of the Leukemia Steering Committee, for their guidance during the development of this platform trial. We are grateful for the advice and encouragement of Dr. Margaret Mooney, Cancer Therapy Evaluation Program. Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers CA180888, CA180819, CA180820, CA180821, and CA180863. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

ASJC Scopus Subject Areas

Hematology

Acceder al documento

10.1002/ajh.24980

Otros archivos y enlaces

Citar esto

Walter, R. B., Michaelis, L. C., Othus, M., Uy, G. L., Radich, J. P., Little, R. F., Hita, S., Saini, L., Foran, J. M., Gerds, A. T., Klepin, H. D., Hay, A. E., Assouline, S., Lancet, J. E., Couban, S., Litzow, M. R., Stone, R. M., & Erba, H. P. (2018). Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. American Journal of Hematology, 93(2), E49-E52. https://doi.org/10.1002/ajh.24980

Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. / Walter, Roland B.; Michaelis, Laura C.; Othus, Megan et al.
En: American Journal of Hematology, Vol. 93, N.º 2, 02.2018, p. E49-E52.

Producción científica: Contribución a una revista › Carta › revisión exhaustiva

Walter, RB, Michaelis, LC, Othus, M, Uy, GL, Radich, JP, Little, RF, Hita, S, Saini, L, Foran, JM, Gerds, AT, Klepin, HD, Hay, AE, Assouline, S, Lancet, JE, Couban, S, Litzow, MR, Stone, RM & Erba, HP 2018, 'Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia', American Journal of Hematology, vol. 93, n.º 2, pp. E49-E52. https://doi.org/10.1002/ajh.24980

@article{89202f53e8cd4976a5521784d145bacd,

title = "Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia",

author = "Walter, {Roland B.} and Michaelis, {Laura C.} and Megan Othus and Uy, {Geoffrey L.} and Radich, {Jerald P.} and Little, {Richard F.} and Sandi Hita and Lalit Saini and Foran, {James M.} and Gerds, {Aaron T.} and Klepin, {Heidi D.} and Hay, {Annette E.} and Sarit Assouline and Lancet, {Jeffrey E.} and Stephen Couban and Litzow, {Mark R.} and Stone, {Richard M.} and Erba, {Harry P.}",

note = "Funding Information: The Older AML Working Group acknowledges Danielle Jenkins (Clinical Information Specialist, the EMMES Corporation) and Dr. Lawrence Baizer (Program Director, Hematologic Malignancies Steering Committees, National Cancer Institute, National Institutes of Health) for their assistance in the organization of our committee. We thank Drs. Wendy Stock, Daniel De Angelo, and Jerry Radich, Co-Chairs of the Leukemia Steering Committee, for their guidance during the development of this platform trial. We are grateful for the advice and encouragement of Dr. Margaret Mooney, Cancer Therapy Evaluation Program. Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers CA180888, CA180819, CA180820, CA180821, and CA180863. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.",

year = "2018",

month = feb,

doi = "10.1002/ajh.24980",

language = "English",

volume = "93",

pages = "E49--E52",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "2",

}

TY - JOUR

T1 - Intergroup LEAP trial (S1612)

T2 - A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia

AU - Walter, Roland B.

AU - Michaelis, Laura C.

AU - Othus, Megan

AU - Uy, Geoffrey L.

AU - Radich, Jerald P.

AU - Little, Richard F.

AU - Hita, Sandi

AU - Saini, Lalit

AU - Foran, James M.

AU - Gerds, Aaron T.

AU - Klepin, Heidi D.

AU - Hay, Annette E.

AU - Assouline, Sarit

AU - Lancet, Jeffrey E.

AU - Couban, Stephen

AU - Litzow, Mark R.

AU - Stone, Richard M.

AU - Erba, Harry P.

N1 - Funding Information: The Older AML Working Group acknowledges Danielle Jenkins (Clinical Information Specialist, the EMMES Corporation) and Dr. Lawrence Baizer (Program Director, Hematologic Malignancies Steering Committees, National Cancer Institute, National Institutes of Health) for their assistance in the organization of our committee. We thank Drs. Wendy Stock, Daniel De Angelo, and Jerry Radich, Co-Chairs of the Leukemia Steering Committee, for their guidance during the development of this platform trial. We are grateful for the advice and encouragement of Dr. Margaret Mooney, Cancer Therapy Evaluation Program. Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers CA180888, CA180819, CA180820, CA180821, and CA180863. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

PY - 2018/2

Y1 - 2018/2

UR - http://www.scopus.com/inward/record.url?scp=85037372411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037372411&partnerID=8YFLogxK

U2 - 10.1002/ajh.24980

DO - 10.1002/ajh.24980

M3 - Letter

C2 - 29164656

AN - SCOPUS:85037372411

SN - 0361-8609

VL - 93

SP - E49-E52

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 2

ER -